Additionally, we found that combination-treated mice developed an antigen-specific CD8+ T-cell immune response as evidenced by mesothelin epitope-specific IFN-γ production and cytotoxicity by splenic CD8+ T cells, also consistent with a pivotal role of CD8+ T cells in mediating tumor protection in these mice. This evidence concerns the gene CD8A and neoplasm.